Taiwan Pharmaceuticals & Healthcare Report Q1 2015 - New Report Available

From: Fast Market Research, Inc.
Published: Tue Dec 23 2014


Taiwan is one of the most attractive and stable prospects in the region for pharmaceutical and healthcare investment, but i s not without flaws. Weaknesses in the country's regulatory regime and drug pricing concerns will continue to deter multinational interest over our forecast period. While our forecasts going into 2015 are unchanged from the previous quarter, BMI believes that Taiwan's export market is poised to benefit greatly from its advantageous position in API manufacturing, and the high regard for Taiwanese private healthcare services in the region.

Headline Expenditure Projections

* Pharmaceuticals: TWD160.66bn (USD5.41bn) in 2013 to TWD167.74bn (USD5.59bn) in 2014; +4.4% in local currency terms and +3.4% in US dollar terms. Forecast unchanged from previous quarter .
* Healthcare: TWD964.25bn (USD32.47bn) in 2013 to TWD1,004.83bn (USD33.49bn) in 2014; +4.2% in local currency terms and +3.2% in US dollar terms. Forecast unchanged from the previous quarter's projections.

Full Report Details at
- http://www.fastmr.com/prod/924306_taiwan_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=301

Risk/Reward Index

Taiwan has moved down one place in our index, from fourth to fifth out of the 19 key markets. We have given the country a score of 64.5 for Q115, down slightly from 65.7 in Q414, resulting in it now coming behind Hong Kong in our regional matrix. While it is a small pharmaceutical market, Taiwan boasts above-average Rewards and Risks, propped up by factors such as high per capita consumption of medicines and an excellent chance to capitalise on the mainland-China market. Taiwan has a very strong active pharmaceutical ingredient (API) industry. Although it is small, which makes the domestic market competitive and particularly constraining, it excels at providing specialty chemicals and high-quality APIs for global needs. The now-annual price adjustments will certainly fuel the need for local companies to outgrow the small domestic market.

Key Trends & Developments

November

The Taiwan Health Reform Foundation (THRF) has claimed that the National...

The Taiwan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Taiwan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Taiwanese pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Taiwan to test other views - a key input for successful budgeting and strategic business planning in the Taiwanese pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q1 2015
- Lebanon Pharmaceuticals & Healthcare Report Q1 2015
- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- India Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »